Counteractive effects of a partial (Sabcomeline) and a full (RS86) muscarinic receptor agonist on deficits in radial maze performance induced by S-AMPA lesions of the basal forebrain and medial septal area

Behavioural Brain Research

Volumn 99, Issue 1, 1999, Pages 81-92

  Hodges, H ^a   Peters, S ^a   Gray, J A ^a   Hunter, A J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Choline acetyltransferase; Cholinergic lesions; Cholinergic muscarinic receptor agonists; Forebrain cholinergic projection system; Radial arm maze; Reference and working memory errors; RS86; Sabcomeline

Indexed keywords

2 ETHYL 8 METHYL 2,8 DIAZASPIRO[4.5]DECANE 1,3 DIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; MUSCARINIC RECEPTOR; SABCOMELINE;

ANIMAL EXPERIMENT; ARTICLE; ASSOCIATION; CHOLINERGIC NERVE; DRUG EFFECT; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; SHORT TERM MEMORY; SPATIAL DISCRIMINATION; SPATIAL MEMORY; TASK PERFORMANCE;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; BASAL GANGLIA; CHOLINE O-ACETYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID AGONISTS; GANGLIONIC STIMULANTS; IMINES; MALE; MAZE LEARNING; MUSCARINIC AGONISTS; NICOTINE; NICOTINIC AGONISTS; PROSENCEPHALON; QUINUCLIDINES; RATS; RATS, SPRAGUE-DAWLEY; SEPTAL NUCLEI; SUCCINIMIDES; TIME FACTORS;

EID: 0033557772     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(98)00075-8     Document Type: Article

References (68)

1. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alterations of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease. J Neurochem 1988;50:1914-23.
2. Arendt T, Bigl V, Arendt A, Tennstedt A. Loss of neurons in the nucleus basalis of meynert in Alzheimer's disease, Paralysis Agitans and Korsakoff's disease. Acta Neuropathol (Berl) 1983;61:101-8.
3. Arendt T, Allen Y, Marchbanks RM, Schugens MM, Sinden J, Lantos PL, Gray JA. Cholinergic system and memory in the rat: effects of chronic ethanol, embryonic basal forebrain transplants, and excitotoxic lesions of the cholinergic basal forebrain projection system. Neuroscience 1989;33(1989):435-62.
4. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-17.
5. Bartus RT, Dean RC, Fisher SK. In: Crook T, Bartus R, Ferris S, Gershon S, editors. Treatment Development Strategies for Alzheimer's Disease. New York: Mark Powley, 1986:421-50.
6. Baxter MG, Bucci DJ, Sobel TJ, Williams J, Gorman LK, Gallagher M. Intact Spatial learning following lesions of basal forebrain cholinergic neurons. Neuro Report 1996;7:1417-20.
7. Becker RE, Giacobini E. Mechanisms of cholinesterase inhibition in senile dementia of the Alzheimer type: clinical pharmacological and therapeutic aspects. Drug Dev Res 1988;12:163-95.
8. Berger-Sweeney J, Heckers S, Mesulam M-M, Wiley RG, Lappi DA, Sharma M. Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J Neurosci 1994;14:4507-19.
9. Blokland A. Acetylcholine - a neurotransmitter for learning and memory. Brain Res Rev 1996;21:285-300.
10. Bradbury EJ, Kershaw TR, Marchbanks RM, Sinden JD. Astrocyte transplants alleviate lesion induced memory deficits independently of cholinergic recovery. Neuroscience 1995;65:955-72.
11. 1 agonist improves cognitive performance in rats. Pharm Biochem Behav 1990;51:667-74.
12. Brown K, Warburton DM. Attenuation of stimulus sensitivity by scopolamine. Psychon Sci 1971;22:297-8.
13. Davey PJ, East S, Rogers D. Tacrine, but not RS86 or Xanomeline, attenuates delay-induced deficits in the rat T-maze. J Psychopharmacol 1995;9:49.
14. Dawson GR, Iversen SD. The effects of novel cholinergic inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav Brain Res 1993;57:143-53.
15. Dawson GR, Bayley P, Channell S, Iversen SD. A comparison of the effects of the novel muscarinic receptor agonists L-689,660 and AF102B in tests of reference and working memory. Psychopharmacology 1994;113:361-8.
16. Dunnett SB. Comparative effects of cholinergic drugs and lesions of the nucleus basalis or fimbria-fornix on delayed matching in rat. Psychopharmacology 1985;87:357-63.
17. Dunnett SB, Fibiger HC. Role of forebrain cholinergic systems in learning and memory: relevance to the cognitive deficits of aging and Alzheimer's disease. Prog Brain Res 1993;98:413-20.
18. Dunnett SB, Everitt BT, Robbins TW. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci 1991;14:494-504.
19. Ensinger HA, Doods HN, Immel-Sehr AR. A muscarinic agonist with preferential neuron-stimulating properties. Life Sci 1993;52:473-80.
20. Everitt BJ, Robbins TW, Evenden JL, Marston HM, Jones JG, Sirkia TE. The effects of excitotoxic lesions of the substantia innominata, ventral and dorsal globus pallidus on the acquisition and retention of a conditional visual discrimination: implications for the cholinergic hypothesis of learning and memory. Neuroscience 1987;22:441-70.
21. 3 muscarinic receptor subtypes in primate brain. Synapse 1993;14:283-96.
22. Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 1975;24:407-9.
23. Hagan JJ, Morris RGM. The cholinergic hypothesis of memory: a review of animal experiments. In: Iversen LL, Iversen SD, Snyder SH, editors. Handbook of Psychopharmacology, vol. 20. New York: Plenum Press, 1988:237-323.
24. 3 receptors. Br J Pharmacol 1992;107:494-501.
25. Haroutunian V, Kanof P, Davis KL. Pharmacological alleviation of cholinergic lesion-induced memory deficits in rats. Life Sci 1985;37:945-52.
26. Haroutunian V, Barnes E, Davis KL. Cholinergic modulation of memory in rats. Psychopharmacology 1985;87:266-71.
27. 1 partial agonist, reverses delay-induced deficits in the rat T-maze at doses which do not induce side effects, (J Pharmacol Exp Ther 1998 (in press).
28. Hodges H, Ribeiro A, Gray JA, Marchbanks RM. Low dose tetrahydroaminoacridine (THA) improves cognitive function in lesioned and alcohol-treated rats but does not affect brain acetylcholine. Pharmacol Biochem Behav 1990;36:291-8.
29. Hodges H, Gray JA, Allen Y, Sinden J. The role of the forebrain cholinergic projection system in performance in the radial-arm maze in memory-impaired rats. In: Adlkofer A, Thurau K, editors. Effects of Nicotine on Biological Systems. Basel: Birkhauser Verlag, 1991:389-99.
30. Hodges H, Sinden J, Turner JJ, Netto CA, Sowinski P, Gray JA. Nicotine as a tool to assess the role of the cholinergic forebrain projection system in cognition. In: Collins AC, Gray JA, Robinson JH, Lipiello PM, editors. The Biology of Nicotin. New York: Raven Press, 1992:157-80.
31. Hodges H, Allen Y, Sinden J, Lantos PL, Gray JA. The effects of cholinergic-rich neural grafts on radial maze performance of rats after excitotoxic lesions of the forebrain cholinergic projection system: 2: cholinergic drugs as probes to investigate lesion-induced deficits and transplant-induced functional recovery. Neuroscience 1991;45:609-23.
32. 3 receptor antagonist, WAY100289, enhances spatial memory in rats with ibotenate lesions of the forebrain cholinergic projection system. Psychopharmacology 1995;117:318-32.
33. 3 receptor antagonists WAY-100579 and ondansetron on spatial learning in the water maze in rats with excitotoxic lesions of the forebrain cholinergic projection system. Psychopharmacology 1996;125:146-61.
34. Jarrard LE. Selective hippocampal lesions and behaviour: implications for current research and theorizing. In: Pribram KH, Isaacson RL, editors. The Hippocampus, 4. New York: Plenum Press, 1986:93-126.
35. Kesner RP, Crutcher KA, Measom MO. Medial septal and nucleus basalis magnocellularis lesions produce order memory deficits in rats which mimic the symptomatology of Alzheimer's disease. Neurobiol Aging 1986;7:287-95.
36. Kopelman MD. The cholinergic neurotransmitter system in human memory and dementia: a review. Quart J Exp Psychol 1986;38A:535-73.
37. Kumar R, Orgogozo J. Efficacy and safety of SB 202026 as a symptomatic treatment for Alzheimer's disease. Neurobiol Aging 1996;17:161.
38. Lehericy S, Hirsch EC, Cervera-Pierot P, Hersh LB, Bakchine S, Piette F, Duyckaerts C, Hauw J-J, Javoy-Agid F, Agid Y. Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease. J Comp Neurol 1993;330:15-31.
39. Levey AI, Kitt CA, Simmonds WF, Price DL, Brann DR. Identification and localisation of muscarinic acetylcholine proteins in brain with subtype-specific antibodies. J Neurosci 1991;11:3218-26.
40. Levey AI. Immunological localisation of M1-M5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993;52:441-8.
41. 1 receptors. J Pharm Exp Ther 1997;283:1059-68.
42. 2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 1985;228:1115-7.
43. Mundy WR, Iwamoto ET. Nicotine impairs acquisition of radial maze performance in rats. Pharmacol Biochem Behav 1988;30:119-22.
44. Page KJ, Everitt BJ, Robbins TW, Marston HM, Wilkinson LS. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuronal loss. Neuroscience 1991;43:457-72.
45. Perry EK, Tomlinson BE, Blessed G, Bergman K, Gibson PH, Perry RH. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978;2:1457-9.
46. Probst A, Ulrich J, Palacios JM. Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer's disease: an autoradiographic study. Brain Res 1988;450:190-201.
47. Quirion R, Aubert I, Lapchak PA, Schaum RP, Teolis S, Gauthier S, Araujo DM. Muscarinic receptor subtypes in human neurodegenerative disorder: focus on Alzheimer's disease. Trends Pharmacol Sci 1989;Dec. Suppl.:80-4.
48. Ridley RM, Murray TK, Johnson JA, Baker HF. Learning impairment following lesions of the nucleus basalis of Meynert in the marmoset: modification by cholinergic drugs. Brain Res 1986;376:108-16.
49. Ridley RM, Baker HF. A critical evaluation of monkey models of amnesia and dementia. Brain Rev 1991;16:15-37.
50. Robbins TW, Everitt BJ, Ryan CN, Marston HM, Jones GH, Page KJ. Comparative effects of quisqualate and ibotenic acid-induced lesions of the substantia innominata and globus pallidus on the acquisition of a conditioned visual discrimination: differential effects on cholinergic mechanisms. Neuroscience 1989;28:337-52.
51. Robbins TW, Everitt BJ, Marston HM, Wilkinson J, Jones GH, Page KJ. Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes. Behav Brain Res 1989;35:221-41.
52. Rupniak NMJ, Steventon MJ, Field MJ, Jennings CA, Iversen SD. Comparison of the effects of four cholinomimetic agents in primates following disruption by scopolamine or by lists of objects. Psychopharmacology 1989;99:189-95.
53. Rusted JM, Warburton DM. Cognitive models and cholinergic drugs. Neuropsychobiology 1989;21:31-6.
54. Saghal A, Keith AB, Lloyd S. Effects of nicotine, oxotremorine, and 9-amino 1,2,3,4-tetrohydroacridine (tacrine) on matching and non-matching to position in rats: no evidence for mnemonic enhancement. J Psychopharmacol 1990;4:210-8.
55. Sahakian B, Jones G, Levy R, Gray JA, Warburton D. The effects of nicotine on attention, information processing and short term memory in patients with dementia of the Alzheimer type. Br J Psychiat 1989;154:797-800.
56. Sedman AJ, Brockbrader H, Schwartz RD. Preclinical and Phase 1 clinical characterisation of CI979/RU35926, a novel muscarinic agonist, for the treatment of Alzheimer's disease. Life Sci 1995;56:877-82.
57. 1 receptors. J Pharm Exp Ther 1994;269:271-81.
58. Steckler T, Keith AB, Wiley RG, Sahgal A. Cholinergic lesions by 192 IgG-saporin and short-term recognition memory: role of the septohippocampal projection. Neuroscience 1995;66:101-14.
59. Sunderland T, Tariot PN, Newhouse PA. Differential responsivity of mood, behaviour and cognition to cholinergic agents in elderly neuro-psychiatric populations. Brain Res Rev 1988;13:371-98.
60. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R. Physical basis of cognitive alteration in Alzheimer's disease-synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-80.
61. Torres EM, Perry T-A, Blokland A, Wilkinson LS, Wiley RG, Lappi DA, Dunnett SB. Behavioural, histochemical and biochemical consequences of selective immunolesion in discrete regions of the basal forebrain cholinergic system. Neurosci Lett 1994;63:95-122.
62. Turner JJ, Hodges H, Sinden JD, Gray JA. Comparison of radial maze performance of rats after ibotenate and quisqualate lesions of the forebrain cholinergic projection system: effects of pharmacological challenge and changes in training regime. Behav Pharmacol 1992;3:359-73.
63. Ueki A, Miyoshi K. Effects of cholinergic drugs on learning impairment in ventral globus pallidus-lesioned rats. J Neruol Sci 1989;90:1-21.
64. Waite JJ, Chen AD, Wardlow ML, Wiley RG, Lappi DA, Thal LJ. 192 immunoglobulin G-saporin produces graded behavioural and biochemical changes accompanying the loss of cholinergic neurons of the basal forebrain and cerebellar Purkinje cells. Neuroscience 1995;65:463-76.
65. Wesnes K, Revell A. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology 1984;84:5-11.
66. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, De Long MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982;215:1237-9.
67. Wilcock GK, Surmon D, Forsyth D, Morgam R. Cholinergic side effects of tetrahydroaminoacridine. Lancet 1988;8623:1305.
68. Yamamura HI, Snyder S. Muscarinic cholinergic binding in rat brain. Proc Nat Acad Sci 1974;71:1725-9.